Dec 13, 2022 | John DeFlice
“The cause is hidden; the effect is visible to all.” Mike Horn Multiple myeloma is a cytogenetically complex blood cancer of the plasma cell, and thesecytogenetic aberrations make it more difficult to treat. Cytogenetics is the study of thebone marrow looking for...
Dec 13, 2022 | Jack Aiello
Today was the final day of ASH, but it was still full of information, and to be honest, I’m a bit brain-fried. For me, the day started with an excellent Education Spotlight session on “Underrepresented minorities in clinical trials…”. It was chaired by multiple...
Dec 11, 2022 | Jill Zitzewitz
The very first session I attended at this year’s American Society of Hematology (ASH) Annual Meeting was a Friday Satellite Symposium sponsored by Clinical Care Options and the International Myeloma Foundation. The symposium title, “A Conversation with the Myeloma...
Dec 10, 2022 | Jessie Daw
Friday, the first day of the 64th Annual American Society of Hematology (ASH) Annual Meeting, is symposia day. I attended the IMF’s Satellite Symposium, “A Conversation with the Myeloma Experts: Making Sense of the Evolving Treatment Landscape.” The experts were the...
Dec 6, 2022 | Teresa Miceli
Hello Myeloma community! It is that time of year again – the 64th American Society of Hematology (ASH) annual meeting, being held in New Orleans, LA (NOLA) from December 10-13, 2022. The Support Group Leaders (SGLs) are back at it for the first Hybrid IMF SGLs@ASH....
